Table 2B. Univariate analysis of prognosis for TUBB3 mRNA.
| FactorTUBB3 | n | 5 y SR | Hazard-ratio | Median survival | Signif. |
|---|---|---|---|---|---|
| (95% CI) | (95% CI) | ||||
| All patients | 280 | 33% | 2.09 (1.8-2.6) y | p=0.0002 | |
| negative | 75 | 48% | Reference | 4.32 (2.1-14.0) y | |
| weak/moderate | 145 | 33% | 1.46 (1.1-2.0) | 2.13 (1.8-2.7) y | |
| strong | 60 | 17% | 2.32 (1.5-3.6) | 1.27 (0.9-1.9) y | |
| Primary surgery | 98 | 46% | 3.37 (1.9-10.0) y | p=0.0304 | |
| negative | 33 | 60% | Reference | 13.21 (3.4-14.0) y | |
| weak/moderate | 52 | 42% | 1.91 (1.1-3.4) | 3.12 (1.7-6.8) y | |
| strong | 13 | 23% | 3.13 (1.2-8.5) | 1.23 (0.4-3.1) y | |
| neoadjuvant | 182 | 25% | 1.88 (1.6-2.2) y | p=0.0305 | |
| negative | 42 | 39% | Reference | 2.09 (1.4-6.5) y | |
| weak/moderate | 93 | 28% | 1.22 (0.8-1.8) | 2.07 (1.8-2.5) y | |
| strong | 47 | 15% | 1.84 (1.1-3.0) | 1.32 (1.0-1.9) y | |
| neoadjuvant | |||||
| minor response | 161 | 23% | 1.85 (1.4-2.2) y | p=0.0055 | |
| negative | 34 | 40% | Reference | 2.16 (1.4-6.5) y | |
| weak/moderate | 87 | 24% | 1.33 (0.9-2.1) | 1.97 (1.5-2.4) y | |
| strong | 40 | 7% | 2.23 (1.3-3.8) | 1.19 (0.9-1.7) y |